Company Profile
Genoskin Inc
Company Overview
Genoskin (https://www.genoskin.com) is a French-American life science company with research facilities in Salem, MA and Toulouse, France. The company creates, develops, and specializes in first-in-human data generation for drug & vaccine developers as well as cosmetic companies and academic institutions.
To generate more accurate human data and deliver the information faster, Genoskin uses IP-protected technologies and platforms that, for the first time, maintain donated human skin tissue in an immunocompetent and functional survival state. The result is true-to-life human skin models that are the closest alternative to in vivo testing on humans and a reliable alternative to animal testing.
Genoskin’s HypoSkin® platform, is the world’s first platform that allows testing injections in human skin ex vivo, in order to provide drug and vaccine makers with an unparalleled de-risking tool for their portfolios.
Genoskin's human skin platforms, empowered by artificial intelligence and machine learning, generate actionable human data ahead of clinical trials and significantly reduce the costs, duration and risks inherent in drug development.
Company History
Genoskin was founded in 2011, as a spin-off of the French National Center for Scientific Research (CNRS) and The Paul Sabatier University in Toulouse. Genoskin won the French National Award for Innovative Technology at its emerging stage in 2010 and was registered as a SAS company (simplified share company) in 2011. In 2012, the company obtained the award from the Réseau Entreprendre Midi-Pyrénées.
In 2018, Genoskin opened new facilities in Salem, MA to better address its North American customers and boost its growth.